TBPH
THERAVANCE BIOPHARMA INC
THERAVANCE BIOPHARMA INC historical holders
total: 2
Baupost Group THERAVANCE BIOPHARMA INC transactions over time
- Total transactions:
- 18
- New positions:
- 1
- Sold out:
- 1
- Added:
- 8
- Reduced:
- 8
- Held since:
- 2014 Q2
- Held for:
- 41 quarters
- Latest activity:
- 2024 Q3
Seth Klarman has been an institutional investor in THERAVANCE BIOPHARMA INC (TBPH) since 2014 Q2. According to 2026 Q1 report, Seth Klarman doesn't hold any shares. The fund/company first acquired TBPH in 2014 Q2, initially purchasing about 6.06M shares. Since the initial investment, Baupost Group has made 17 more transactions in this position.
When did Seth Klarman exit their TBPH position?
Seth Klarman no longer holds THERAVANCE BIOPHARMA INC (TBPH). They sold off their entire position in 2024 Q3, closing out an investment that began in 2014 Q2.
When did Seth Klarman first invest in TBPH?
Seth Klarman first invested in THERAVANCE BIOPHARMA INC (TBPH) in 2014 Q2 at the reported quarter-end price of $31.88 per share, acquiring 6,061,228 shares in their initial purchase.
What is Seth Klarman's average cost basis for TBPH?
Based on historical transaction data, Seth Klarman's estimated cost basis for THERAVANCE BIOPHARMA INC (TBPH) is approximately $23.00 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $23.00
- Weighted AVG sell price:
- $9.72
TBPH transactions history by Baupost Group
18 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2024 Q3
|
0.00%
|
0
|
$8.48
|
|
-100% (-4,200,021)
|
-0.98%
|
|
2024 Q2
|
0.98%
|
4,200,021
|
$8.48
|
$35,616,000
|
-36.31% (-2,394,105)
|
-0.56%
|
|
2024 Q1
|
1.62%
|
6,594,126
|
$8.97
|
$59,149,000
|
-11.12% (-825,100)
|
-0.16%
|
|
2023 Q2
|
1.37%
|
7,419,226
|
$10.35
|
$76,789,000
|
-28.79% (-3,000,000)
|
-0.53%
|
|
2023 Q1
|
1.93%
|
10,419,226
|
$10.85
|
$113,049,000
|
-8.76% (-1,000,000)
|
-0.18%
|
|
2022 Q4
|
2.09%
|
11,419,226
|
$11.22
|
$128,124,000
|
-14.90% (-2,000,000)
|
-0.39%
|
|
2022 Q2
|
1.80%
|
13,419,226
|
$9.06
|
$121,578,000
|
-1.64% (-224,107)
|
-0.02%
|
|
2022 Q1
|
1.40%
|
13,643,333
|
$9.56
|
$130,430,000
|
-0.12% (-16,835)
|
-0%
|
|
2021 Q3
|
0.93%
|
13,660,168
|
$7.40
|
$101,085,000
|
+37.84% (+3,750,000)
|
+0.25%
|
|
2021 Q2
|
1.17%
|
9,910,168
|
$14.52
|
$143,896,000
|
+13.45% (+1,175,000)
|
+0.14%
|
|
2020 Q3
|
1.40%
|
$14.78
|
-6.17% (-574,000)
|
|||
|
2017 Q3
|
3.97%
|
$34.24
|
+0.38% (+35,177)
|
|||
|
2016 Q4
|
3.85%
|
$31.88
|
+26.16% (+1,923,000)
|
|||
|
2016 Q2
|
2.26%
|
$22.69
|
+13.07% (+850,000)
|
|||
|
2016 Q1
|
1.76%
|
$18.80
|
+1.26% (+80,963)
|
|||
|
2015 Q2
|
1.39%
|
$13.02
|
+0.84% (+53,451)
|
|||
|
2015 Q1
|
1.86%
|
$17.35
|
+5.04% (+305,349)
|
|||
|
2014 Q2
|
3.15%
|
$31.88
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.